Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb;76(2):510-532.
doi: 10.1111/all.14452. Epub 2020 Sep 3.

Clinical characteristics of 182 pediatric COVID-19 patients with different severities and allergic status

Affiliations

Clinical characteristics of 182 pediatric COVID-19 patients with different severities and allergic status

Hui Du et al. Allergy. 2021 Feb.

Abstract

Background: The pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has made widespread impact recently. We aim to investigate the clinical characteristics of COVID-19 children with different severities and allergic status.

Methods: Data extracted from the electronic medical records, including demographics, clinical manifestations, comorbidities, laboratory and immunological results, and radiological images of 182 hospitalized COVID-19 children, were summarized and analyzed.

Results: The median age was 6 years, ranging from 3 days to 15 years, and there were more boys (male-female ratio about 2:1) within the studied 182 patients. Most of the children were infected by family members. Fever (43.4%) and dry cough (44.5%) were common symptoms, and gastrointestinal manifestations accounted for 11.0%, including diarrhea, abdominal discomfort, and vomiting. 71.4% had abnormal chest computed tomography (CT) scan images, and typical signs of pneumonia were ground-glass opacity and local patchy shadowing on admission. Laboratory results were mostly within normal ranges, and only a small ratio of lymphopenia (3.9%) and eosinopenia (29.5%) were observed. The majority (97.8%) of infected children were not severe, and 24 (13.2%) of them had asymptomatic infections. Compared to children without pneumonia (manifested as asymptomatic and acute upper respiratory infection), children with pneumonia were associated with higher percentages of the comorbidity history, symptoms of fever and cough, and increased levels of serum procalcitonin, alkaline phosphatase, and serum interleukins (IL)-2, IL-4, IL-6, IL-10, and TNF-α. There were no differences in treatments, duration of hospitalization, time from first positive to first negative nucleic acid testing, and outcomes between children with mild pneumonia and without pneumonia. All the hospitalized COVID-19 children had recovered except one death due to intussusception and sepsis. In 43 allergic children with COVID-19, allergic rhinitis (83.7%) was the major disease, followed by drug allergy, atopic dermatitis, food allergy, and asthma. Demographics and clinical features were not significantly different between allergic and nonallergic groups. Allergic patients showed less increase in acute phase reactants, procalcitonin, D-dimer, and aspartate aminotransferase levels compared with all patients. Immunological profiles including circulating T, B, and NK lymphocyte subsets, total immunoglobulin and complement levels, and serum cytokines did not show any difference in allergic and pneumonia groups. Neither eosinophil counts nor serum total immunoglobulin E (IgE) levels showed a significant correlation with other immunological measures, such as other immunoglobulins, complements, lymphocyte subset numbers, and serum cytokine levels.

Conclusion: Pediatric COVID-19 patients tended to have a mild clinical course. Patients with pneumonia had higher proportion of fever and cough and increased inflammatory biomarkers than those without pneumonia. There was no difference between allergic and nonallergic COVID-19 children in disease incidence, clinical features, and laboratory and immunological findings. Allergy was not a risk factor for developing and severity of SARS-CoV-2 infection and hardly influenced the disease course of COVID-19 in children.

Keywords: COVID-19; SARS-CoV-2; allergy; children; lymphocyte subsets; pneumonia.

PubMed Disclaimer

Conflict of interest statement

Dr Akdis reports grants from Allergopharma, Idorsia, Swiss National Science Foundation, Christine Kühne‐Center for Allergy Research and Education, European Commission's Horizon 2020 Framework Programme, Cure, Novartis Research Institutes, Astra Zeneca, and Scibase, and for advisory role in Sanofi/Regeneron, outside the submitted work. Dr Cao, Dr Li, Dr Liu, Dr Chen, Dr Du, Dr Zhang, Prof. Akdis M, Dr Huang, Dr Dong, Dr Lu, and Dr Gao have nothing to disclose.

Figures

Figure 1
Figure 1
The comparisons in the duration of hospitalization and the time of negative conversion of RT‐PCR assays for SARS‐CoV‐2 nucleic acid, respectively, between the following COVID‐19 subgroups: (A, B), allergic and nonallergic patients; (C, D), no pneumonia and mild pneumonia patients; and (E, F), patients aged <10 years and ≥10 years. In each graph, the dots denote each of the numerical values, the middle long lines denote medians, and bilateral short lines denote interquartile ranges. In particular, the black dots denote the numerical values of three severe/critical cases, and the hollow black dot denotes those of one dead case. Details of these four severe or critically ill patients are presented in Table 7. All of the comparisons were not significantly different (P > .05). RT‐PCR, real‐time reverse transcription‐polymerase chain reaction. (+), positive
Figure 2
Figure 2
Typical chest CT images of pediatric COVID‐19 patients. A, A 11‐month‐old nonallergic female, with chest CT showing ground‐glass opacity in left lower lobe; B, a 1‐year‐old nonallergic male, with chest CT showing bilateral ground‐glass opacities and subpleural nodular consolidation; C, a 4‐year‐old boy with a history of allergic rhinitis, and his chest CT showed patchy opacities in left lower lobe; D, a 3‐year‐old boy with a history of allergic rhinitis and recurrent wheezing, and his chest CT showed patchy opacity distributed around the bronchovascular bundle in right lower lobe
Figure 3
Figure 3
Heatmap of correlation matrix between duration of hospitalization (DH), duration of RT‐PCR conversion (DP, time from first positive to first negative RT‐PCR results), blood cell counts and immunological parameters of pediatric patients with COVID‐19 in (A) total cases (n = 182), (B) allergic cases (n = 43), and (C) mild pneumonia cases (n = 124), respectively. Analyzed variables included numbers of immune cells, serum levels of immunoglobulins (Igs), complements, and cytokines: NEU (neutrophil count, ×109/L), EOS (eosinophil count, ×109/L), LYM (lymphocyte count, ×109/L), T (T‐cell count,/μL), CD4+ and CD 8+ T (CD4+ and CD8+ T‐cell count,/μL), B (B‐cell count,/μL), NK (natural killer cell count,/μL), IgG, IgA, and IgM (concentration, g/L), IgE (concentration, IU/mL), C3 and C4 (complements C3 and C4 concentration, g/L), IL‐2, IL‐4, IL‐6, and IL‐10 (interleukin concentration, pg/mL), TNF‐α (tumor necrosis factor‐α concentration, pg/mL), and IFN‐γ (interferon‐γ, pg/mL). The values of Spearman's correlation coefficients are shown in each cell of the graph. Red and blue backgrounds stand for positive and negative correlations, respectively, and the shades of color reflect the strength of correlation
Figure 4
Figure 4
Correlations between the duration of hospitalization and the time of RT‐PCR conversion in pediatric COVID‐19 patients: (A) all patients, (B) allergic patients, (C) patients with pneumonia, (D) the significantly negative correlation between the duration of hospitalization and the level of IFN‐γ in patients with pneumonia. Spearman's correlation test was used, with a calculation of correlation coefficient (r). The red dots denote the numerical values of three severe/critical cases, and the hollow red dot denotes those of one dead case. RT‐PCR, real‐time reverse transcription‐polymerase chain reaction. (+), positive; (−), negative

Similar articles

Cited by

References

    1. Wuhan Municipal Health Commission . Report of clustering pneumonia of unknown etiology in Wuhan City, 2019.
    1. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020;382:727‐733. - PMC - PubMed
    1. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020;579:270‐273. - PMC - PubMed
    1. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses . The species Severe acute respiratory syndrome‐related coronavirus: classifying 2019‐nCoV and naming it SARS‐CoV‐2. Nat Microbiol. 2020;5:536‐544. - PMC - PubMed
    1. World Health Organization (WHO) . Responding to community spread of COVID‐19 (Interim guidance) 7 March 2020. https://www.who.int/publications‐detail/responding‐to‐community‐spread‐o... Accessed April 23, 2020.